RPS26 appears to function as both a biomarker and a contributor to immune tolerance during SLIT. Its association with IL-10 induction, regulatory T-cell expansion, apoptosis resistance, and TET2/TET3 expression suggests a translational-epigenetic axis supporting allergen desensitization. These findings highlight ribosomal specialization as a determinant of immunotherapy responsiveness. Larger studies are needed to validate RPS26 and further define its mechanistic role in allergen-specific immunotherapy.
Nakayoshi et al. (Fri,) studied this question.